Study S001266

A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01098461
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 215
Start: 2010-04
Primary completion: 2011-05
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:albiglutide; BIOLOGICAL:placebo
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 [Baseline and Week 16]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0038091	A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus Seino, Yutaka, Figshare	2020	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01098461
R0018591	Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Young MA, Postgraduate medicine	2014	Other trial	PMID 25387217 DOI	cites ClinicalTrials.gov:NCT01098461; registry reference DERIVED:25387217
R0025670	A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Seino Y, Current medical research and opinion	2014	Randomized trial	PMID 24552155 DOI	cites ClinicalTrials.gov:NCT01098461; registry reference DERIVED:24552155